MCRB - Earnings announcements

Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, expected in Q2 2026 SER-155 is Phase 2 ready for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematologic malignancies (cancers of the blood, bone marrow, and lymph nodes); efforts to secure funding for the program

Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Efforts are ongoing to obtain capital and other resources to support SER-155 Phase 2 study; pending securing funding, interim clinical results anticipated within 12 months of study initiation Ongoing investigator-sponsored study in immune checkpoint related enterocolitis expected to inform broader SER-155 opportunity; initial study results anticipated in early 2026 Seres recently implemented actions to reduce operating costs; based on these

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on November 5, 2025 at 8:30 a.m. ET to discuss third quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 8471287. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website shortly after the event and will be archi

Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure capital and other resources to enable the clinical advancement of SER-155 and additional live biotherapeutic product candidates Seres received the $25 million installment payment, as expected, from Nestlé Health Science in July 2025 Conference call at 8:30 a.m. ET today CAM

CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at 8:30 a.m. ET to discuss second quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 3641971. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours afte

In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support broader potential for Seres' live biotherapeutics to address inflammatory and immune diseases Seres advancing SER-155 strategic partnership discussions i

CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4618787. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours aft

Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) at day 30 post-HSCT; Company expects to submit draft study protocol to FDA in Q2 2025 SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, are consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support potential for live biotherapeutics to address inflammatory and immune diseases Company advances SER-155 strategic partnership discussions to acce

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) --  Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on March 13, 2025 at 8:30 a.m. ET to discuss fourth quarter and full year 2024 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 6331602. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately tw

SER-155 Phase 1b placebo-controlled clinical results demonstrated significant reduction in both bacterial bloodstream infections and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia, as compared to placebo, through day 100 post allo-HSCT Financial position strengthened following completion of VOWST™ sale; based on existing cash, projected 2025 deal economics and current operating plans, Seres expects to fund operations into Q4 2025 Seeking SER-155 strategic partnership to accelerate next study in allo-HSCT and expand to multiple target populations Conference call at 8:30 a.m. ET today CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIR

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on November 13, 2024 at 8:30 a.m. ET to discuss third quarter 2024 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 5051385. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours after

SER-155 administration was associated with a significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia, as compared to placebo through day 100 post HSCT Demonstrated generally well tolerated safety profile and confirmed drug bacteria strain engraftment; no treatment-related serious adverse events Company to seek Breakthrough Therapy designation from the FDA, given the high unmet medical need associated with BSIs, and discuss plans to advance development of SER-155 in allo-HSCT Results support Seres' strategy to pursue SER-155 and other live biotherapeutics for prevention of a broader range of

SER-155 Phase 1b placebo-controlled Cohort 2 clinical readout on track for September VOWST asset sale to provide $175M cash infusion, less approximately $20M in settlement of net obligations between the Parties, at close Transaction proceeds to fully retire debt and support advancement of wholly-owned cultivated live biotherapeutic pipeline to improve patient outcomes in medically vulnerable populations Based on existing cash, deal economics and operating plans, Seres expects to fund operations into Q4 2025 Conference call at 8:30 a.m. ET today CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), ("Seres" or "the Company"),

Upon closing, Seres to receive $175M cash infusion, including an upfront payment, prepayment of a future commercial milestone payment, and an equity investment in Seres common stock, less approximately $20M in settlement of net obligations between the Parties; anticipated deal closing in the next 90 days Additional approximately $75M in cash payments are due to Seres in 2025, contingent upon Seres' compliance with transition obligations, with the potential for additional future commercial milestone payments of up to $275M on the achievement of VOWST net sales targets Seres will fully retire its debt obligations upon closing Based on existing cash, deal economics and oper

CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 13, 2024 at 8:30 a.m. ET to discuss second quarter 2024 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4877586. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours after t

Continued market adoption of VOWST® with approximately 1,411 patient enrollment forms received, approximately 1,083 new patient starts, and net sales of $10.1 million during Q1 2024, and accelerated net sales in March and April SER-155 Phase 1b placebo-controlled Cohort 2 clinical readout expected end of Q3 2024 Further microbiome therapeutic candidates have potential to expand product franchise into additional medically vulnerable patient populations Conference call at 8:30 a.m. ET today Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today reported first quarter 2024 financial results and provided business updates. "With a broad indication and

Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 8, 2024 at 8:30 a.m. ET to discuss first quarter 2024 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 5686561. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 da

VOWST net sales of $10.4 million for the fourth quarter of 2023 and $19.6 million since launch in June through year-end 2023 Significant adoption of VOWST since launch in June 2023 through year-end 2023 with 2,833 patient enrollment forms received and 2,015 new patient starts SER-155 Phase 1b placebo-controlled Cohort 2 clinical data anticipated in third quarter of 2024 Conference call at 8:30 a.m. ET today Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided business updates. "2023 was an historic year for Seres as we launched our first-in-class oral microbiome therapeuti

Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 5, 2024 at 8:30 a.m. ET to discuss fourth quarter and full year 2023 results and provide a general business update. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4030622. To join the live webcast, please visit the "Investor and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for appr

Rapid growth of VOWST continues with more than 1,500 patient enrollment forms received since FDA approval Announces strategic restructuring to focus resources and investment on continued VOWST growth, completion of SER-155 Phase 1b study, and supporting longer-term business sustainability Reduction of current workforce by 41%; total anticipated 2024 annual cash savings of $75-$85 million and cash runway expected into the fourth quarter of 2024 Conference call at 8:00 a.m. ET today Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today reported financial results for the third quarter ended September 30, 2023, including VOWST net sales of $7.6 million

Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced that it will release third quarter 2023 financial results on Thursday, November 2, 2023. Management will host a conference call with investors to discuss the results and corporate updates at 8:00 a.m. ET. The conference call may be accessed by calling 1-866-777-2509 (international callers dial 1-412-317-5413). Participants may pre-register for the conference call at https://dpregister.com/sreg/10184132/faf729b9c0 To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres websit

– VOWSTTM is the first orally administered microbiome therapeutic FDA-approved for prevention of recurrence of C. difficile infection in adults following antibacterial treatment for recurrent CDI (rCDI) – – VOWST early commercial uptake encouraging with strong initial demand observed across healthcare provider specialties and rCDI patient profiles, including first recurrence – – SER-155 Phase 1b Cohort 1 clinical data showed favorable tolerability, successful drug bacteria engraftment and a substantial reduction in pathogen domination in the gastrointestinal microbiome; Cohort 2 data readout anticipated in mid-2024 – – Conference call at 8:30 a.m. ET today – Seres Therapeutics, Inc.

Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 8, 2023 at 8:30 a.m. ET to discuss second quarter results and provide a general business update. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4844622. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days

– VOWST™ microbiota-based therapeutic approved for prevention of recurrence of C. difficile infection in adults following antibacterial treatment for recurrent CDI; product availability expected in June – – New SER-155 Phase 1b Cohort 1 clinical data show favorable tolerability, successful drug bacteria engraftment and a significant reduction in pathogen domination in the gastrointestinal microbiome; Cohort 2 data readout anticipated in mid-2024 – – Strengthened balance sheet with up to $250 million debt facility with Oaktree, Seres received $110 million upon agreement closing; Seres to receive $125 million milestone payment from Nestlé Health Science related to VOWST approval – – Con

– Tolerability profile observed supports continued development in Cohort 2, with no treatment attributed serious adverse events – – Reduction in incidences of microbiome pathogen domination provides support for intended SER-155 clinical activity – –SER-155 Phase 1b placebo-controlled Cohort 2 data readout anticipated in mid-2024 – – Conference call at 8:30 a.m. ET today – Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today reported initial clinical data about SER-155. SER-155 is an oral, cultivated bacterial consortia investigational therapeutic designed to prevent enteric-derived infections and resulting blood stream infections, as well as induc

- Company to report initial SER-155 Phase 1b safety and pharmacology results from study Cohort 1 - Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 9, 2023 at 8:30 a.m. ET to discuss first quarter results and provide a general business update, including initial SER-155 Phase 1b safety and pharmacology results from study Cohort 1. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 5098595. To join the live webcast, please visit the "Investors and News" section of the Seres website

– First and only FDA-approved orally administered microbiota-based therapeutic, validating Seres' microbiome platform – – Phase 3 ECOSPOR III study demonstrated that 88% of treated individuals were recurrence-free at 8 weeks – – Opportunity to address prevention of recurrence of C. difficile infection in adults with rCDI, including first recurrence, following antibacterial treatment – – VOWST product availability expected in June – – Conference call at 8:30 a.m. ET tomorrow – Seres Therapeutics, Inc. (NASDAQ:MCRB) and Nestlé Health Science today announced the U.S. Food and Drug Administration (FDA) approval of VOWSTTM (fecal microbiota spores, live-brpk), formerly called SER-109,

– SER-109 Biologics License Application (BLA) under review with U.S. Food and Drug Administration (FDA) with target action date of April 26, 2023 under Prescription Drug User Fee Act (PDUFA) – – Anticipate SER-109 commercial launch soon after potential FDA approval decision – – SER-155 Phase 1b study cohort 2 enrollment ongoing; anticipate reporting initial SER-155 safety and pharmacological data from Cohort 1 in May 2023 – – Conference call at 8:30 a.m. ET today – Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2022 financial results and provided business updates. "We are eagerly looking forward to the upco

Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 7, 2023 at 8:30 a.m. ET to discuss fourth quarter and full year 2022 results and provide a general business update. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4218669. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for appro

– Event to highlight recurrent CDI market opportunity and SER-109 launch preparations – Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced that it will host an investor webcast to discuss the planned commercialization approach and market opportunity for therapeutic candidate SER-109 in recurrent C. difficile infection (rCDI) on Thursday, December 8, 2022, at 8:30 a.m. ET and is expected to be approximately one hour in duration. In October 2022, Seres announced its Biologics License Application for SER-109 was accepted for Priority Review by the FDA and that a Prescription Drug User Fee Act (PDUFA) action date has been set for April 26, 2023.

Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on November 2, 2022, at 8:30 a.m. ET to discuss third quarter 2022 results and provide a general business update. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference conference ID 8315051. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days. Abo

Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 3, 2022, at 8:30 a.m. ET to discuss second quarter 2022 results and provide a general business update. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference conference ID 3171491. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days. Abou

– ECOSPOR IV study shows favorable safety profile through 24-week follow-up, consistent with the safety profile observed in ECOSPOR III study – 91.3% sustained clinical response achieved at eight weeks in overall population with consistent results in key subpopulations including first recurrence – – Rolling Biologics License Application (BLA) submission initiated and on track for mid-2022 completion – – Conference call at 8:30 a.m. ET today – Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced confirmatory results from ECOSPOR IV, an open-label study for SER-109, an investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI). The overall

– SER-109 open label study results, including safety and efficacy data, including in over 260 individuals enrolled with recurrent C. difficile infection, anticipated in Q2 2022 – – FDA agreement obtained for rolling SER-109 Biologics License Application (BLA) plan; filing completion on track for mid-2022 – – SER-109 pre-commercialization activities underway, including medical education and payer engagement – – Conference call at 8:30 a.m. ET today – Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates. "Seres continued to make important progress toward bringing SER-109 to pat

Seres Therapeutics, Inc. (NASDAQ:MCRB) a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 4, 2022 at 8:30 a.m. ET to discuss first quarter 2022 results and provide a general business update. To access the conference call, please dial 877-270-2148 (domestic) or 412-902-6510 (international) and request to be joined to the Seres Therapeutics call. To join the live webcast, please visit the "Investors and Media" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately

– SER-109 Phase 3 study results in recurrent C. difficile infection published in New England Journal of Medicine – Biologics License Application (BLA) filing for SER-109 anticipated in mid-2022 – – Investor webcast highlighted the broad potential of microbiome therapeutics as a novel approach for Infection Protection in medically compromised individuals – – Conference call at 8:30 a.m. ET today – Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2021 financial results and provided business updates. "The progress made throughout 2021 has set the stage for an exciting year ahead for Seres, highlighted by the ant

  Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 1, 2022 at 8:30 a.m. ET to discuss fourth quarter and full year 2021 results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 6277858. To join the live webcast, please visit the "Investors and Media" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for a

Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced that it will host a webcast investor event on Monday, January 31, 2022, from 8:30 a.m. to 10:00 a.m. ET. The event will focus on the development of microbiome therapeutics as a novel approach for infection protection in medically compromised individuals. Clinical data from the Company's Phase 3 ECOSPOR III trial found SER-109, an investigational oral microbiome therapeutic, to be superior to placebo in reducing CDI recurrence, with 88% of SER-109 patients achieving a sustained clinical response compared to 60% on placebo. Building upon SER-109, Seres is currently evaluating SER-155 in a Phase

– Enrollment completed in SER-109 recurrent C. difficile infection open-label study –  – Company expects both completed SER-109 Phase 3 study results and pending safety database to support finalization of Biologics License Application (BLA) filing in mid-2022 – – Collaboration with Bacthera A.G., a global leader in biopharmaceutical product manufacturing, expands existing capabilities for commercial product supply – – SER-109 expanded access program initiated for adults with recurrent C. difficile infection  – – Conference call at 8:30 a.m. ET today – Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today reported third quarter 2021 financial results a

Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on November 10, 2021 at 8:30 a.m. ET to discuss third quarter 2021 results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 1275436. To join the live webcast, please visit the "Investors and Media" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 2

– SER-109 open-label study in patients with recurrent C. difficile infection on track to achieve enrollment target in late Q3 2021 – – SER-109 co-commercialization agreement with Nestlé Health Science provides $310 million in upfront and contingent approval milestones, additional $225 million in contingent sales milestones, and future payments equal to 50% of profits – – Microbiome analyses from SER-287 Phase 2b ulcerative colitis study anticipated in H2 2021 – – Continued clinical development progress with SER-155 and SER-301, next-generation rationally designed pipeline candidates – – Conference call at 8:30 a.m. ET today – Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome

Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast today at 8:30 a.m. ET to discuss topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC). To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 5155278. To join the live webcast, please visit the "Investors and Media" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours after the

—Primary endpoint of clinical remission compared to placebo was not achieved— —Both dosing regimens of SER-287 were generally well tolerated— —Open label and maintenance portions of the SER-287 study will be closed— — Microbiome endpoints and analyses expected in the second half of 2021— —Company to host a conference call at 8:30 a.m. ET— Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC). The study did not meet its primary endpoint of improving clinical remission rates compared to placebo. Both dosing regimens of